Clinical trial

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

NCT00538681

Study summary

ClinicalTrials.gov

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention enzastaurin Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record pemetrexed Normalized identity: pemetrexed View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record cisplatin Normalized identity: cisplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2007-09-01

PhasePHASE2

Conditions

Lung Cancerverified · MONDO: lung cancer

Interventions

enzastaurinDRUG

pemetrexedDRUG · verified · RxNorm: pemetrexed

cisplatinDRUG · verified · RxNorm: cisplatin

placeboDRUG

Sponsors & collaborators

Eli Lilly and Companylead sponsor

Mapped research locations

HamburgGermany1 LeuvenBelgium1 BucharestRomania1 PoznanPoland1 HeidelbergGermany1 PadovaItaly1 CataniaItaly1 BergamoItaly1 GautingGermany1 OtwockPoland1 TrentoItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00538681 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.